ER-D5 antigen immune radiometric assay in breast cancer research.
A trial of 185 breast cancer tissues has been developed to characterize receptor negative tumors. We observed the ER-D5-Ag availability to recognize the hormone sensitivity inside the receptor-negative patient groups. In Pre-M ER--ve patients, we observed 26.9%-29.4% of D5+ve cases and in PgR--ve 50% of D5+ve cases. In Post-M ER--ve patients, we observed 31.2%-36.5% of D5+ve cases and in PgR--ve 53.2% of D5+ve cases. The reproducibility of our results suggests the relevance of an additional investigation to characterize the hormonal sensitivity of receptor-negative breast cancer tissues.
Nardelli
G B
GB
Institute of Obstetrics and Gynaecology, University of Padua, Italy.
D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000032:analysis*; D002352:Carrier Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008593:Menopause; D011863:Radioimmunoassay; D011960:Receptors, Estrogen / Q000032:analysis*
D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D011960:Receptors, Estrogen; C010140:estrophilin